01/13/22 7:00 AMNasdaq : SLRX acquisitionSalarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLCConference call and live audio webcast scheduled for today at 8:30 a.m. EST Transformative acquisition significantly expands Salarius’ oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area of cancer drugRHEA-AIneutral
01/06/22 12:45 PMNasdaq : SLRX conferencesSalarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022"Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that the company will present at H.C. Wainwright BioConnectRHEA-AIneutral
12/29/21 8:03 AMNasdaq : SLRX clinical trialSalarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma TrialRHEA-AIneutral
12/15/21 8:31 AMNasdaq : SLRX conferencesSalarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, ChiefRHEA-AIneutral
11/29/21 8:01 AMNasdaq : SLRX conferencesSalarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One ConferenceSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid cancers, announced today that its chief executiveRHEA-AIneutral
11/04/21 4:05 PMNasdaq : SLRX earningsSalarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company ProgressCash and Cash Equivalents of $31.9 Million Sufficient to Fund Completion of Ongoing Clinical Trials for Lead Drug Candidate Seclidemstat Added Five New Clinical Sites to Sarcoma Trial; 13 Active Sites Now Supporting Enrollment Initial Ewing Sarcoma Combination Therapy Safety Lead-in Cohort FullyRHEA-AIneutral
10/26/21 8:01 AMNasdaq : SLRX conferencesearningsSalarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company ProgressSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,RHEA-AIneutral
10/07/21 9:05 AMNasdaq : SLRX Salarius Pharmaceuticals and Nationwide Children’s Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide Children’s Hospital announced today researchRHEA-AIneutral
10/05/21 8:01 AMNasdaq : SLRX conferencesSalarius Pharmaceuticals to Present at the 2021 BioFuture ConferenceSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, ChiefRHEA-AIneutral
09/30/21 4:35 PMNasdaq : SLRX Salarius Pharmaceuticals and Nationwide Children’s Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide Children’s Hospital disclosed today that anRHEA-AIneutral